Projects dedicated to drug research and development, with a focus on access to essential therapies and strengthening pharmaceutical safety.

Development and innovation in health

Project title – INOVA a+ RESEARCH AND DEVELOPMENT CENTER AND CRITICAL MEDICINE PRODUCTION

Funder – Ministry of Investments and European Projects

Funding Program – Health Program, Priority 9.A – Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector.

Total project value – 452,683,403.74 lei

EU contribution – 181,281,786.00 lei

Project description: – The investment in the “INOVA a+ Research and Development Center and Critical Medicine Production” aims to strengthen the company’s position in the field of research and production of critical medicines at national and European level. The initiative includes two main components: the development of research capabilities and the expansion of production capacities. The research component aims to develop the Inova a+ Center, facilitating the expansion and diversification of the portfolio of critical medicines produced in Romania, in line with European priorities. The project integrates modern laboratories, facilitating the subsequent transfer of advanced technology. It will also include the sustainable synthesis of active substances through “green” processes and nanotechnology research for targeted drug therapies.

The production component involves investing in a modern capacity for critical medicines in the form of sterile injectable beta-lactam powders divided into vials – a field in which Antibiotice has global expertise. The production from this new capacity will ensure both the need for critical medicines for hospitals in Romania and for healthcare systems at European level.

Implementation period: 48 months, between 11.11.2025 – 10.11.2029

March 19, 2026 – PRESS RELEASE regarding:
LAUNCH OF THE PROJECT “INOVA a+ RESEARCH-DEVELOPMENT CENTER AND CRITICAL MEDICINE PRODUCTION”
SMIS code 342451

Project financed through the state aid scheme by the Ministry of Public Finance

Project title – CAPACITY FOR PRODUCTION, PACKAGING AND STORAGE OF STERILE PRODUCTS, SOLUTIONS AND TOPICALS

Financer – Ministry of Finance

Financing Program – State aid scheme GD 807/2014, through the Ministry of Finance

Total project value – approximately 54 million EUR / 265 million lei (updated 2026), of which 34 million EUR / 170 million lei eligible costs

MF contribution (state aid) – 17.27 million EUR / 85 million lei (HG 807/2014)

Project description: The project aims to strengthen the company’s capacities in the field of production and distribution of sterile medicines, by developing new product lines and the related logistics infrastructure, with financing from national funds. The initiative is structured around three main components: the production of sterile injectable solutions, the development of sterile topical products and the expansion of storage and logistics capacities.

The production component aims to create a modern capacity for obtaining sterile injectable solutions, intended to become operational starting in 2027, with the resulting products being introduced on the market, most likely, in 2030. In parallel, the project includes the development of a range of sterile topical products, with an estimated launch date on the Romanian market in 2030, in accordance with the authorization stages specific to the pharmaceutical field.

The logistics component involves the development of a warehouse dedicated to finished products, authorized by the National Medicines Agency in 2025, ensuring optimal storage and distribution conditions in accordance with the standards in force.

By implementing the project “Capacity for production, packaging and storage of sterile products, solutions and topicals”, the company contributes to diversifying the portfolio of sterile medicines available on the Romanian market, facilitating the healthcare system’s access to new types of essential treatments, intended for use in hospitals and other medical facilities, both nationally and on foreign markets.

Implementation period: 2023 – 2029